Increase of peroxisome proliferator-activated receptor δ (PPARδ) by digoxin to improve lipid metabolism in the heart of diabetic rats

Hormone and Metabolic Research

Volumn 45, Issue 5, 2013, Pages 364-371

  Chen, Z C ^a,b   Yu, B C ^c   Chen, L J ^c   Cheng, J T ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

cardiomyocytes; digoxin; fatty acid oxidation genes; PPAR ; siRNA

Indexed keywords

CALCIUM ION; CHELATE; DIGOXIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; FATTY ACID OXIDATION; HEART; HEART MUSCLE CELL; HYPERGLYCEMIA; LIPID METABOLISM; LIPID STORAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANIMALS, NEWBORN; DIABETES MELLITUS, EXPERIMENTAL; DIGOXIN; EGTAZIC ACID; FATTY ACIDS; GENE EXPRESSION REGULATION; HYPERGLYCEMIA; LIPID METABOLISM; MYOCARDIUM; MYOCYTES, CARDIAC; OXIDATION-REDUCTION; PPAR DELTA; RATS; RNA, SMALL INTERFERING;

RATTUS;

EID: 84877875108     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1330021     Document Type: Article

References (40)

1. Kannel W. B., Hjortland M., Castelli W. P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol: 1974; 34 29 34
2. Kannel W. B., McGee D. L. Diabetes and cardiovascular disease. The Framingham study. JAMA: 1979; 241 2035 2038 (Pubitemid 9228506)
3. Malmberg K., Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J: 1988; 9 259 264
4. Herlitz J., Malmberg K., Karlson B. W., Ryden L., Hjalmarson A. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand: 1988; 224 31 38
5. Poornima I. G., Parikh P., Shannon R. P. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res: 2006; 98 596 605
6. An D., Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol: 2006; 291 H1489 H1506 (Pubitemid 44497651)
7. Besch H. R. Jr, Watanabe A. M. The positive inotropic effect of digitoxin: independence from sodium accumulation. The Journal of pharmacology and experimental therapeutics: 1978; 207 958 965 (Pubitemid 9100501)
8. Pervaiz M. H., Dickinson M. G., Yamani M. Is digoxin a drug of the past? Cleve Clin J Med: 2006; 73 821 824 826, 829-832 passim
9. van Veldhuisen D. J., Manin't Veld A. J., Dunselman P. H., Lok D. J., Dohmen H. J., Poortermans J. C., Withagen A. J., Pasteuning W. H., Brouwer J., Lie K. I. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J Am Coll Cardiol: 1993; 22 1564 1573 (Pubitemid 23336707)
10. Ahmed A., Pitt B., Rahimtoola S. H., Waagstein F., White M., Love T. E., Braunwald E. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol: 2008; 123 138 146 (Pubitemid 350258580)
11. Yang Q., Li Y. Roles of PPARs on regulating myocardial energy and lipid homeostasis. J Mol Med: 2007; 85 697 706 (Pubitemid 47063523)
12. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature: 1990; 347 645 650
13. Cheng L., Ding G., Qin Q., Huang Y., Lewis W., He N., Evans R. M., Schneider M. D., Brako F. A., Xiao Y., Chen Y. E., Yang Q. Cardiomyocyte- restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med: 2004; 10 1245 1250 (Pubitemid 39540443)
14. Cheng L., Ding G., Qin Q., Xiao Y., Woods D., Chen Y. E., Yang Q. Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun: 2004; 313 277 286 (Pubitemid 37543582)
15. Barish G. D., Narkar V. A., Evans R. M. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest: 2006; 116 590 597 (Pubitemid 43326863)
16. Planavila A., Rodriguez-Calvo R., Jove M., Michalik L., Wahli W., Laguna J. C., Vazquez-Carrera M. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res: 2005; 65 832 841 (Pubitemid 40249728)
17. Pesant M., Sueur S., Dutartre P., Tallandier M., Grimaldi P. A., Rochette L., Connat J. L. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res: 2006; 69 440 449 (Pubitemid 43098800)
18. Finck B. N., Kelly D. P. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation: 2007; 115 2540 2548 (Pubitemid 46763228)
19. Rimbaud S., Garnier A., Ventura-Clapier R. Mitochondrial biogenesis in cardiac pathophysiology. Pharmacol Rep: 2009; 61 131 138
20. Yu B. C., Chang C. K., Ou H. Y., Cheng K. C., Cheng J. T. Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc Res: 2008; 80 78 87
21. Ventura-Clapier R., Garnier A., Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res: 2008; 79 208 217 (Pubitemid 351951611)
22. Sack M. N., Kelly D. P. The energy substrate switch during development of heart failure: gene regulatory mechanisms (Review). Int J Mol Med: 1998; 1 17 24
23. Bugger H., Abe E. D. Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci: 2008; 114 195 210 (Pubitemid 351293995)
24. Fein F. S., Kornstein L. B., Strobeck J. E., Capasso J. M., Sonnenblick E. H. Altered myocardial mechanics in diabetic rats. Circ Res: 1980; 47 922 933 (Pubitemid 11217058)
25. Fein F. S., Strobeck J. E., Malhotra A., Scheuer J., Sonnenblick E. H. Reversibility of diabetic cardiomyopathy with insulin in rats. Circ Res: 1981; 49 1251 1261 (Pubitemid 12246594)
26. Chen Z. C., Yu B. C., Chen L. J., Cheng K. C., Lin H. J., Cheng J. T. Characterization of the mechanisms of the increase in PPARdelta expression induced by digoxin in the heart using the H9c2 cell line. Br J Pharmacol: 2011; 163 390 398
27. Naya F. J., Mercer B., Shelton J., Richardson J. A., Williams R. S., Olson E. N. Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J Biol Chem: 2000; 275 4545 4548 (Pubitemid 30108834)
28. Passier R., Zeng H., Frey N., Naya F. J., Nicol R. L., McKinsey T. A., Overbeek P., Richardson J. A., Grant S. R., Olson E. N. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest: 2000; 105 1395 1406 (Pubitemid 30322405)
29. Schiaffino S., Serrano A. Calcineurin signaling and neural control of skeletal muscle fiber type and size. Trends Pharmacol Sci: 2002; 23 569 575 (Pubitemid 35375802)
30. Hokanson J. F., Mercier J. G., Brooks G. A. Cyclosporine A decreases rat skeletal muscle mitochondrial respiration in vitro. Am J Respir Crit Care Med: 1995; 151 1848 1851
31. Zhou L., Cabrera M. E., Okere I. C., Sharma N., Stanley W. C. Regulation of myocardial substrate metabolism during increased energy expenditure: insights from computational studies. Am J Physiol Heart Circ Physiol: 2006; 291 H1036 H1046 (Pubitemid 44343647)
32. Shkryl V. M., Shirokova N. Transfer and tunneling of Ca2+ from sarcoplasmic reticulum to mitochondria in skeletal muscle. J Biol Chem: 2006; 281 1547 1554
33. Schaeffer P. J., Wende A. R., Magee C. J., Neilson J. R., Leone T. C., Chen F., Kelly D. P. Calcineurin and calcium/calmodulin-dependent protein kinase activate distinct metabolic gene regulatory programs in cardiac muscle. J Biol Chem: 2004; 279 39593 39603 (Pubitemid 39258226)
34. Tate C. A., Hyek M. F., Taffet G. E. The role of calcium in the energetics of contracting skeletal muscle. Sports Med: 1991; 12 208 217
35. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology: 1996; 137 354 366 (Pubitemid 26005011)
36. Takahashi S., Tanaka T., Sakai J. New therapeutic target for metabolic syndrome: PPARdelta. Endocr J: 2007; 54 347 357 (Pubitemid 47105421)
37. Wang Y. X., Zhang C. L., Yu R. T., Cho H. K., Nelson M. C., Bayuga-Ocampo C. R., Ham J., Kang H., Evans R. M. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol: 2004; 2 e294
38. Lin J., Wu H., Tarr P. T., Zhang C. Y., Wu Z., Boss O., Michael L. F., Puigserver P., Isotani E., Olson E. N., Lowell B. B., Bassel-Duby R., Spiegelman B. M. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature: 2002; 418 797 801
39. Luquet S., Lopez-Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M., Grimaldi P. A. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J: 2003; 17 2299 2301 (Pubitemid 39561472)
40. Kleiner S., Nguyen-Tran V., Bare O., Huang X., Spiegelman B., Wu Z. PPAR {delta} agonism activates fatty acid oxidation via PGC-1{alpha} but does not increase mitochondrial gene expression and function. J Biol Chem: 2009; 284 18624 18633